Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menveo is approved for use in persons 2 months through 55 years of age. Menveo does not prevent N. meningitidis serogroup B infections.Important Safety Information
You should not receive MENVEO if you have had a severe allergic reaction to any ingredient of the vaccine, or if you have had a severe allergic reaction to a vaccine containing similar components as MENVEO.
Common side effects from MENVEO include pain and redness at the injection site, headache, muscle pain, fatigue, nausea, and fainting. In infants under 2 years old, persistent crying, sleepiness, and diarrhea were also observed. Sometimes fainting is accompanied by falling with injury. Other side effects can also occur.
Tell your healthcare provider if you were previously diagnosed with Guillain-Barré syndrome (GBS - severe muscle weakness).
Tell your healthcare provider if you are pregnant, or plan to become pregnant. If your baby was born prematurely, let your healthcare provider know prior to getting your baby vaccinated with MENVEO.
Tell your healthcare provider if you have problems with your immune system, as your immune response to the vaccine may be less.
Vaccination with MENVEO may not protect all individuals. For more information about MENVEO, talk to your healthcare professional.
Menveo.com has been developed by Novartis Vaccines as part of the company’s commitment to individual and public health.
This site is sponsored by Novartis Vaccines and Diagnostics, Inc.
Copyright © 2011 Novartis Vaccines and Diagnostics, Inc. All rights reserved.
Menveo is a registered trademark of Novartis Vaccines AG. NVDMEN422
Menveo.com Exit Notice